Zomedica Completes Renovation & Upgrade of Manufacturing, Distribution, and R&D Center in Plymouth, Minnesota
Zomedica Corp. (NYSE American:ZOM) has completed renovations at its 30,000-square-foot facility in Plymouth, Minnesota. The upgrades include an expanded cleanroom for manufacturing operations, installation of a new automated line for TRUFORMA® cartridge production, and improved distribution facilities for more efficient shipping. The new automated cartridge line can produce up to one million cartridges annually, significantly increasing manufacturing capacity to meet growing demand.
The TRUFORMA diagnostic platform uses Qorvo Inc.'s Bulk Acoustic Wave (BAW) sensor technology, offering veterinarians precise diagnostic measurements for thyroid and adrenal conditions, canine non-infectious gastrointestinal disease, and equine Cushing's disease. This renovation strengthens Zomedica's ability to meet customer demand while developing its expanding assay portfolio.
Zomedica Corp. (NYSE American:ZOM) ha completato i lavori di ristrutturazione presso il suo stabilimento di 30.000 piedi quadrati a Plymouth, Minnesota. Gli aggiornamenti includono un cleanroom ampliato per le operazioni di produzione, l'installazione di una nuova linea automatizzata per la produzione di cartucce TRUFORMA®, e miglioramenti nelle strutture di distribuzione per una spedizione più efficiente. La nuova linea automatizzata di cartucce può produrre fino a un milione di cartucce all'anno, aumentando significativamente la capacità produttiva per soddisfare la crescente domanda.
La piattaforma diagnostica TRUFORMA utilizza la tecnologia dei sensori a onde acustiche di massa (BAW) di Qorvo Inc., offrendo ai veterinari misurazioni diagnostiche precise per le condizioni tiroidee e surrenali, malattie gastrointestinali non infettive nei cani e la malattia di Cushing nei cavalli. Questa ristrutturazione rafforza la capacità di Zomedica di soddisfare la domanda dei clienti mentre sviluppa il suo portafoglio di saggi in espansione.
Zomedica Corp. (NYSE American:ZOM) ha completado las renovaciones en su instalación de 30,000 pies cuadrados en Plymouth, Minnesota. Las mejoras incluyen una sala limpia ampliada para las operaciones de fabricación, la instalación de una nueva línea automatizada para la producción de cartuchos TRUFORMA®, y facilidades de distribución mejoradas para un envío más eficiente. La nueva línea automatizada de cartuchos puede producir hasta un millón de cartuchos anuales, aumentando significativamente la capacidad de fabricación para satisfacer la creciente demanda.
La plataforma de diagnóstico TRUFORMA utiliza la tecnología de sensores de onda acústica de masa (BAW) de Qorvo Inc., ofreciendo a los veterinarios mediciones diagnósticas precisas para condiciones tiroideas y suprarrenales, enfermedades gastrointestinales no infecciosas en perros, y la enfermedad de Cushing en caballos. Esta renovación refuerza la capacidad de Zomedica para satisfacer la demanda de los clientes mientras desarrolla su creciente cartera de ensayos.
조메디카(Zomedica Corp.) (NYSE American:ZOM)는 미네소타주 플리머스에 있는 30,000제곱피트 시설의 리노베이션을 완료했습니다. 업그레이드에는 제조 작업을 위한 확장된 클린룸, TRUFORMA® 카트리지 생산을 위한 새로운 자동화 라인 설치, 및 보다 효율적인 배송을 위한 개선된 유통 시설이 포함됩니다. 새로운 자동화 카트리지 라인은 연간 100만 개의 카트리지를 생산할 수 있어, 증가하는 수요를 충족하기 위해 제조 능력을 크게 확장합니다.
TRUFORMA 진단 플랫폼은 Qorvo Inc.의 대량 음향 파동(BAW) 센서 기술을 사용하여 수의사에게 갑상선 및 부신 질환, 개의 비감염성 위장질환, 그리고 말의 쿠싱병에 대한 정확한 진단 측정을 제공합니다. 이 리노베이션은 고객의 수요에 부응하고 있는 Zomedica의 역량을 강화하면서 그들의 확장된 검사 포트폴리오를 개발하는 데 도움을 줍니다.
Zomedica Corp. (NYSE American:ZOM) a terminé les rénovations de son installation de 30 000 pieds carrés à Plymouth, Minnesota. Les améliorations comprennent une salle blanche agrandie pour les opérations de fabrication, l'installation d'une nouvelle ligne automatisée pour la production de cartouches TRUFORMA®, et des installations de distribution améliorées pour un expédition plus efficace. La nouvelle ligne de cartouches automatisée peut produire jusqu'à un million de cartouches par an, augmentant considérablement la capacité de production pour répondre à la demande croissante.
La plateforme de diagnostic TRUFORMA utilise la technologie de capteurs à ondes acoustiques de masse (BAW) de Qorvo Inc., offrant aux vétérinaires des mesures diagnostiques précises pour les conditions thyroïdiennes et surrénaliennes, la maladie gastro-intestinale non infectieuse chez les chiens et la maladie de Cushing chez les chevaux. Cette rénovation renforce la capacité de Zomedica à répondre à la demande des clients tout en développant son portefeuille d'essais en expansion.
Zomedica Corp. (NYSE American:ZOM) hat die Renovierungsarbeiten an seiner 30.000 Quadratfuß großen Einrichtung in Plymouth, Minnesota, abgeschlossen. Die Verbesserungen umfassen einen erweiterten Reinraum für die Fertigungsoperationen, die Installation einer neuen automatisierten Linie für die Produktion von TRUFORMA®-Kartuschen und verbesserte Vertriebsanlagen für effizientere Versandmöglichkeiten. Die neue automatisierte Kartuschenlinie kann bis zu eine Million Kartuschen jährlich produzieren, was die Produktionskapazität erheblich erhöht, um der wachsenden Nachfrage gerecht zu werden.
Die TRUFORMA-Diagnoseplattform nutzt die Bulk Acoustic Wave (BAW)-Sensortechnologie von Qorvo Inc. und bietet Tierärzten präzise diagnostische Messungen für Schilddrüsen- und Nebennierenbedingungen, nichtinfektiöse gastrointestinalen Erkrankungen bei Hunden und das Cushing-Syndrom bei Pferden. Diese Renovierung stärkt die Fähigkeit von Zomedica, die Kundennachfrage zu decken und gleichzeitig das wachsende Portfolio an Tests weiterzuentwickeln.
- Expanded cleanroom and improved distribution facilities enhance manufacturing capacity
- New automated production line can produce up to one million TRUFORMA cartridges annually
- Increased manufacturing capacity to meet rising customer demand
- Improved efficiency in production and distribution processes
- None.
Insights
The completion of Zomedica's facility renovation in Plymouth, Minnesota, marks a significant operational milestone. The expanded cleanroom and new automated production line for TRUFORMA cartridges are key enhancements that could substantially boost manufacturing capacity. With the potential to produce up to
The improved distribution facilities should streamline shipping processes, potentially reducing costs and improving delivery times. These operational improvements are likely to enhance Zomedica's competitive position in the veterinary diagnostics market. However, investors should monitor whether these enhancements translate into increased sales and market share in the coming quarters.
Zomedica's investment in upgrading its manufacturing and R&D facilities demonstrates a commitment to scaling its TRUFORMA diagnostic platform. The Bulk Acoustic Wave (BAW) sensor technology, licensed from Qorvo Inc., offers a unique value proposition in veterinary diagnostics. By providing reference-lab quality results at the point of care, TRUFORMA addresses a critical need in veterinary practice.
The expanded R&D capabilities could accelerate the development of new assays, potentially broadening TRUFORMA's application range. This could be particularly impactful in areas like thyroid and adrenal conditions, canine gastrointestinal disease and equine Cushing's disease. Investors should watch for announcements of new assays or expanded indications, as these could drive adoption and revenue growth.
Expanded cleanroom and improved distribution facilities enhance manufacturing capacity and shipping efficiencies
ANN ARBOR, MI / ACCESSWIRE / September 11, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering diagnostic and therapeutic products for equine and companion animals, is pleased to announce the completion of renovations at its 30,000-square-foot manufacturing, distribution, and research and development (R&D) facility in Plymouth, Minnesota.
Highlights of the renovation include:
Expanded cleanroom for manufacturing operations
Installation and validation of new automated line to produce TRUFORMA® consumable cartridges
Improved distribution facilities for more efficient and streamlined shipping of TRUFORMA cartridges
"With the steady growth of our TRUFORMA product line, these facility renovations, and new automated production equipment have increased manufacturing capacity which we believe will meet increasing demand for TRUFORMA cartridges for years to come," stated Larry Heaton, Zomedica's Chief Executive Officer. "This latest upgrade strengthens our ability to meet rising customer demand while continuing to develop our expanding assay portfolio."
"This renovation is an important step in keeping us positioned for success," stated Tony Blair, Zomedica's Executive Vice President and Chief Operating Officer. "I am pleased to share that we have completed all our necessary testing and validation, and customer cartridges are now being produced on our automated cartridge line. The new state-of-the-art TRUFORMA cartridge line can produce up to one million cartridges annually and will drive new levels of efficiencies in addition to significantly bolstering our manufacturing capacity. We remain dedicated to expanding our manufacturing and distribution capabilities to deliver the high-quality products our customers deserve."
The TRUFORMA diagnostic platform utilizes Qorvo Inc.'s proprietary Bulk Acoustic Wave (BAW) sensor technology, providing veterinarians with highly precise and sensitive diagnostic measurements. The TRUFORMA system offers an advantage over traditional optical-based technologies, enabling more accurate diagnosis and treatment of complex thyroid and adrenal conditions, canine non-infectious gastrointestinal disease, and equine Cushing's disease. The system provides reference-lab quality results at the point of care, enhancing convenience and clinical decision-making.
About Zomedica
Zomedica is a leading equine and companion animal healthcare company dedicated to improving animal health by providing veterinarians innovative therapeutic and diagnostic solutions. Our gold standard PulseVet® shock wave system, which accelerates healing in musculoskeletal conditions, has transformed veterinary therapeutics. Our suite of products also includes the Assisi® Loop line of therapeutic devices and the TRUFORMA® diagnostic platform, the TRUVIEW™ digital cytology system, and the VetGuardian® no-touch monitoring system, all designed to empower veterinarians to provide top-tier care. In the aggregate, their total addressable market in the U.S. exceeds
Follow Zomedica
Email Alerts: http://investors.zomedica.com
Facebook: https://m.facebook.com/zomedica
X (formerly Twitter): https://twitter.com/zomedica
Instagram: https://www.instagram.com/zomedica_inc
Cautionary Note Regarding Forward-Looking Statements
Except for statements of historical fact, this news release contains certain "forward-looking information" or "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur and include statements relating to our expectations regarding future results. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance, or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.
Forward-looking information is based on the opinions and estimates of management at the date the statements are made, including assumptions with respect to economic growth, demand for the Company's products, the Company's ability to produce and sell its products, sufficiency of our budgeted capital and operating expenditures, the satisfaction by our strategic partners of their obligations under our commercial agreements, our ability to realize upon our business plans and cost control efforts and the impact of COVID-19 on our business, results and financial condition.
Our forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: the outcome of clinical studies, the application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments, uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the timing and results of development work and verification and validation studies; uncertainty as to the timing and results of commercialization efforts, as well as the cost of commercialization efforts, including the cost to develop an internal sales force and manage our growth; uncertainty as to our ability to successfully integrate acquisitions; uncertainty as to our ability to supply products in response to customer demand; uncertainty as to the likelihood and timing of any required regulatory approvals, and the availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; veterinary acceptance of our products; competition from related products; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; performance by our strategic partners of their obligations under our commercial agreements, including product manufacturing obligations; risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to any required clinical trials and regulatory approvals, risks relating to the safety and efficacy of our products, the use of our products, intellectual property protection, risks related to the COVID-19 pandemic and its impact upon our business operations generally, including our ability to develop and commercialize our products, and the other risk factors disclosed in our filings with the SEC and under our profile on SEDAR+ at www.sedarplus.com. Readers are cautioned that this list of risk factors should not be construed as exhaustive.
The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.
Investor Relations Contact:
Zomedica Investor Relations
investors@zomedica.com
1-734-369-2555
SOURCE: Zomedica Corp.
View the original press release on accesswire.com
FAQ
What renovations did Zomedica (ZOM) complete at its Plymouth, Minnesota facility?
How many TRUFORMA cartridges can Zomedica's (ZOM) new automated line produce annually?
What technology does Zomedica's (ZOM) TRUFORMA diagnostic platform use?
What conditions can Zomedica's (ZOM) TRUFORMA system diagnose?
